BRPI0416938A - agente de formação de imagem, composição, conjugado, kit para a preparação da composição radiofarmacêutica - Google Patents

agente de formação de imagem, composição, conjugado, kit para a preparação da composição radiofarmacêutica

Info

Publication number
BRPI0416938A
BRPI0416938A BRPI0416938-7A BRPI0416938A BRPI0416938A BR PI0416938 A BRPI0416938 A BR PI0416938A BR PI0416938 A BRPI0416938 A BR PI0416938A BR PI0416938 A BRPI0416938 A BR PI0416938A
Authority
BR
Brazil
Prior art keywords
composition
imaging
imaging agents
conjugate
kit
Prior art date
Application number
BRPI0416938-7A
Other languages
English (en)
Inventor
Duncan Hiscock
Ben Newton
Benedicte Guilbert
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of BRPI0416938A publication Critical patent/BRPI0416938A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0429—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K51/0431—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)

Abstract

"AGENTE DE FORMAçãO DE IMAGEM, COMPOSIçãO, CONJUGADO, KIT PARA A PREPARAçãO DA COMPOSIçãO RADIOFARMACêUTICA". A presente invenção diz respeito a agentes de formação de imagem diagnóstico para formação de imagem in vivo. Os agentes de formação de imagem compreendem um inibidor sintético da caspase-3 rotulado com uma porção de formação de imagem adequada para formação de imagem diagnóstico in vivo. A invenção também fornece composições farmacêuticas e radiofarmacêuticas que compreendem os agentes de formação de imagem, junto com kits para a preparação dos radiofármacos. Acham-se também descritos conjugados de quelação do inibidor da caspase-3, os quais são adequados para a preparação dos agentes de formação de imagem compreendendo um íon de metal radioativo ou paramagnético. Os agentes de formação de imagem são úteis para formação de imagem diagnóstico e/ou para monitorar a terapia in vivo dos vários estados de doença em que a caspase-3 esteja envolvida.
BRPI0416938-7A 2003-11-26 2004-11-26 agente de formação de imagem, composição, conjugado, kit para a preparação da composição radiofarmacêutica BRPI0416938A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0327494.1A GB0327494D0 (en) 2003-11-26 2003-11-26 Novel imaging agents
PCT/GB2004/005003 WO2005053752A2 (en) 2003-11-26 2004-11-26 Novel imaging agents comprising caspase-3 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0416938A true BRPI0416938A (pt) 2007-02-13

Family

ID=29797853

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416938-7A BRPI0416938A (pt) 2003-11-26 2004-11-26 agente de formação de imagem, composição, conjugado, kit para a preparação da composição radiofarmacêutica

Country Status (15)

Country Link
US (1) US20060275215A1 (pt)
EP (1) EP1763371A2 (pt)
JP (1) JP2007512302A (pt)
KR (1) KR101236124B1 (pt)
CN (1) CN1905904B (pt)
AU (1) AU2004294784B2 (pt)
BR (1) BRPI0416938A (pt)
CA (1) CA2547236A1 (pt)
GB (1) GB0327494D0 (pt)
IL (1) IL175667A (pt)
MX (1) MXPA06006045A (pt)
NO (1) NO20062387L (pt)
RU (1) RU2006117819A (pt)
WO (1) WO2005053752A2 (pt)
ZA (1) ZA200603887B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006156A2 (en) * 2004-07-08 2006-01-19 Nst Neurosurvival Technologies Ltd Compounds/methods for detection of medical disorders
WO2006074799A2 (en) * 2005-01-17 2006-07-20 Universitätsklinikum Münster 5-pyrrolidinylsulfonyl isatin derivatives
GB0502277D0 (en) * 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
AU2006306592A1 (en) * 2005-10-21 2007-05-03 Immunochemistry Technologies, Llc In vivo detection of apoptosis
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
GB0612333D0 (en) * 2006-06-21 2006-08-02 Ge Healthcare Ltd Radiopharmaceutical products
CA2654369C (en) * 2006-06-21 2014-10-14 Ge Healthcare Limited Radiopharmaceutical products
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
KR100845010B1 (ko) * 2007-08-29 2008-07-08 한국생명공학연구원 Ｎｉｒ／ｍｒ 이중모드 분자영상용 고분자 입자 및 그제조방법
WO2009134405A2 (en) * 2008-04-30 2009-11-05 Siemens Medical Solutions Usa, Inc. Novel substrate based pet imaging agents
US20110165611A1 (en) * 2008-09-04 2011-07-07 Chun Li Dual modality detection of apoptosis
JP5667056B2 (ja) 2008-09-05 2015-02-12 インペリアル・イノベイションズ・リミテッド インビボ画像化剤として使用されるイサチン誘導体
GB0818738D0 (en) * 2008-10-13 2008-11-19 Ge Healthcare Ltd Imaging neuroflammation
WO2014186737A1 (en) * 2013-05-16 2014-11-20 The Johns Hopkins University Compositions and methods for chemical exchange saturation transfer (cest) based magnetic resonance imaging (mri)
WO2017053864A1 (en) * 2015-09-23 2017-03-30 Intracellular Technologies, Llc Cysteine protease inhibitors
CN107655871A (zh) * 2017-09-12 2018-02-02 重庆医科大学 一种阿仑膦酸钠的高灵敏宽检测范围荧光检测新方法
CA3239611A1 (en) * 2021-12-08 2023-06-15 Hui Xiong Compounds specific to granzyme b and uses thereof
EP4724061A2 (en) * 2023-06-07 2026-04-15 Cytosite Biopharma Inc. Prodrugs for compounds specific to granzyme b and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601801A (en) * 1994-08-02 1997-02-11 Merck Frosst Canada, Inc. Radiolabelled angiotensin converting enzyme inhibitors
AR016384A1 (es) * 1997-07-30 2001-07-04 Smithkline Beecham Corp Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta.
US6589503B1 (en) * 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
WO2001089584A2 (en) * 2000-05-23 2001-11-29 Amersham Health As Contrast agents
NO20002644D0 (no) * 2000-05-23 2000-05-23 Nycomed Imaging As Kontrastmiddel
JP4190290B2 (ja) * 2001-03-02 2008-12-03 ユニバーシティー オブ ウエスタン オンタリオ 放射能標識された化合物のポリマー前駆体、ならびにその作製および使用法
US20060147378A1 (en) * 2002-09-24 2006-07-06 Ching-Hsuan Tung Azulene dimer-quenched, near-infrared fluorescent probes
EP1594819A1 (en) * 2003-02-07 2005-11-16 Merck Frosst Canada & Co. Irreversible caspase-3 inhibitors as active site probes
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa

Also Published As

Publication number Publication date
KR20060123196A (ko) 2006-12-01
AU2004294784A1 (en) 2005-06-16
GB0327494D0 (en) 2003-12-31
US20060275215A1 (en) 2006-12-07
CA2547236A1 (en) 2005-06-16
CN1905904A (zh) 2007-01-31
WO2005053752A2 (en) 2005-06-16
MXPA06006045A (es) 2006-08-23
IL175667A (en) 2013-09-30
AU2004294784B2 (en) 2008-04-24
RU2006117819A (ru) 2008-01-10
KR101236124B1 (ko) 2013-02-21
NO20062387L (no) 2006-05-31
JP2007512302A (ja) 2007-05-17
CN1905904B (zh) 2011-12-21
ZA200603887B (en) 2008-02-27
WO2005053752A3 (en) 2005-10-06
IL175667A0 (en) 2006-09-05
EP1763371A2 (en) 2007-03-21

Similar Documents

Publication Publication Date Title
Keen et al. Imaging apoptosis in vivo using 124I-annexin V and PET
BRPI0507684A (pt) agentes de contraste para formação de imagem de perfusão miocárdica
BRPI0416528A (pt) agente de formação de imagem, composição farmacêutica, composição radiofarmacêutica, conjugado, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
Naqvi et al. Ciprofloxacin: from infection therapy to molecular imaging
IL175667A (en) Imaging agent which comrises a synthetic caspase-3 inhibitor labeled with an imaging moiety, a radiopharmaceutical composition comprising the same, a kit for the preparation of said composition and a method of diagnosis based thereon
HRP20170857T1 (hr) Derivati stirilpiridina i njihova uporaba za vezanje i snimanje amiloidnih naslaga
BRPI0408236A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
BRPI0507824A (pt) hidroxiapatita, processo para a preparação de um particulado de hidroxiapatita marcada com radionuclìdeo, composição farmacêutica, uso de hidroxiapatita e de um radionuclìdeo emissor de alfa ou um radionuclìdeo emissor de beta, dispositivo, e, método de tratamento radioquìmico de um ser humano ou de um indivìduo animal não humano necessitando do mesmo
BR0113251A (pt) Compostos, composição cosmética, composição farmacêutica, uso cosmético de uma composição e uso de um composto
UY27003A1 (es) Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
DE602004028731D1 (de) Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
BRPI0510487A (pt) agentes de contraste para estudo por imagens de perfusão do miocárdio
Reichl et al. Uptake, clearance and metabolism of TEGDMA in guinea pigs
BR0317349A (pt) Droga sólida para uso oral
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
Zhao et al. Highly efficient one-pot labeling of new phosphonium cations with fluorine-18 as potential PET agents for myocardial perfusion imaging
JP2002519440A5 (pt)
BRPI0518328A2 (pt) agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica
Qin et al. A tri-modal molecular imaging agent for sentinel lymph node mapping
WO2004100998A3 (en) Compositions and methods for non-invasive imaging of soluble beta-amyloid
Lipowska et al. Al18F-NODA-butyric acid: biological evaluation of a new PET renal radiotracer
BRPI0515894A (pt) agente de formação de imagem, composições farmacêutica e radiofarmacêutica, conjugado de um inibidor de metaloproteinase matricial com um ligando, precursor para a preparação da composição radiofarmacêutica, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
WO2007115132A3 (en) Radiopharmaceutical in self-forming liposomal formulation capable of multipath administration including other ingredients
Reichl et al. Toxicokinetic of HEMA in guinea pigs

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.